Fingerprint
Dive into the research topics of 'Cabozantinib as a second-line treatment option in hepatocellular carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello
Research output: Contribution to journal › Review article › peer-review
4
Citations
(SciVal)
8
Downloads
(Pure)